Want to see AU:EPN full AI Analyst Report?
Top Page
Epsilon Healthcare Limited
(Sydney:EPN)
Select Model
Select Model
Rating:52Neutral
Price Target:
AU$0.02
▲(5.00% Upside)
Action:Reiterated
Date:09/24/26
The score is held back primarily by weak underlying profitability and elevated leverage despite improving revenue/margins and a meaningful cash-flow turnaround. Technicals are supportive with an established uptrend, but the high P/E and lack of dividend support create valuation risk.
Positive Factors
Revenue and Gross Margin Improvement
Strong top-line growth alongside a materially higher gross margin indicates improving scale and economics in the underlying business. If maintained, this combination can support operating leverage, strengthen reinvestment capacity, and provide a foundation for more durable profitability over the next several quarters.
Negative Factors
Operating Profitability Remains Negative
Revenue and gross margin improvements have not yet translated into robust operating earnings. Negative EBIT and EBITDA margins leave limited protection against execution setbacks, while the near-breakeven net margin suggests the recent improvement remains fragile and requires sustained growth and cost control to become durable.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and Gross Margin Improvement
Strong top-line growth alongside a materially higher gross margin indicates improving scale and economics in the underlying business. If maintained, this combination can support operating leverage, strengthen reinvestment capacity, and provide a foundation for more durable profitability over the next several quarters.
Read all positive factors
Epsilon Healthcare Limited (EPN) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$7.78M
Dividend YieldN/A
Average Volume (3M)79.17K
Price to Earnings (P/E)66.7
Beta (1Y)-0.48
Revenue Growth121.40%
EPS GrowthN/A
CountryAU
Employees14
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)<0.01
Shares Outstanding389,104,000
10 Day Avg. Volume109,301
30 Day Avg. Volume79,168
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)6.55
Price to Sales (P/S)1.33
P/FCF Ratio-3.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Epsilon Healthcare Limited Business Overview & Revenue Model
Company Description
Epsilon Healthcare Limited operates as an Australian-based healthcare and pharmaceutical firm, with significant operations also extending into Canada. Established in 2016 and headquartered in Sydney, the company specializes in several areas: manuf...
How the Company Makes Money
null...
Epsilon Healthcare Limited Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
38
Negative
Cash Flow
62
Positive
| Breakdown | TTM | Dec 2025 | Jun 2025 | Dec 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 20.37M | 9.39M | 5.60M | 6.65M | 7.11M | 5.50M |
| Gross Profit | 6.92M | 2.09M | 4.17M | 4.81M | 725.85K | 2.06M |
| EBITDA | -694.10K | -1.86M | -2.13M | -937.07K | -10.86M | -8.03M |
| Net Income | 96.58K | -1.28M | -3.25M | -1.09M | -13.29M | -9.24M |
Balance Sheet | ||||||
| Total Assets | 19.47M | 17.87M | 22.26M | 14.41M | 20.50M | 30.55M |
| Cash, Cash Equivalents and Short-Term Investments | 1.29M | 242.86K | 1.57M | 343.01K | 809.60K | 2.34M |
| Total Debt | 8.69M | 10.35M | 7.88M | 3.45M | 3.20M | 4.44M |
| Total Liabilities | 15.59M | 15.95M | 11.57M | 6.87M | 11.23M | 10.98M |
| Stockholders Equity | 3.88M | 1.91M | 10.70M | 7.54M | 9.27M | 19.57M |
Cash Flow | ||||||
| Free Cash Flow | 975.73K | -3.30M | -3.50M | -803.47K | -3.10M | -6.18M |
| Operating Cash Flow | 1.12M | -3.13M | -3.41M | -703.37K | -2.57M | -5.43M |
| Investing Cash Flow | -703.93K | 6.29M | -97.73K | -99.12K | -529.40K | -737.59K |
| Financing Cash Flow | 131.29K | -4.48M | 4.73M | 335.91K | 1.61M | 1.47M |
Epsilon Healthcare Limited Technical Analysis
Negative
0.02
Price Trends
0.02
Negative
0.02
Negative
0.02
Negative
Market Momentum
>-0.01
Positive
37.70
Neutral
27.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EPN, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 37.70 is Neutral, neither overbought nor oversold. The STOCH value of 27.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:EPN.
Epsilon Healthcare Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | AU$147.70M | 13.70 | 19.91% | 5.29% | 12.19% | 22.36% | |
64 Neutral | AU$41.12M | 65.18 | 1.13% | 0.49% | 8.99% | 450.00% | |
52 Neutral | AU$7.78M | 66.67 | 3.34% | ― | 121.40% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$49.68M | -13.04 | -1.67% | ― | 15.21% | -141.82% | |
44 Neutral | AU$18.20M | -6.88 | -13.81% | 6.27% | 5.93% | 66.32% | |
39 Underperform | AU$21.43M | -5.07 | 4388.00% | ― | -19.73% | 50.34% |
* Healthcare Sector Average
AU:EPN
Epsilon Healthcare Limited
0.02
>-0.01
-16.67%
AU:VLS
Vita Life Sciences Limited
2.74
0.47
20.76%
AU:LGP
Little Green Pharma Ltd.
0.06
-0.07
-53.85%
AU:MVP
Medical Developments International Limited
0.37
-0.33
-47.86%
AU:PKP
Althea Group Holdings Ltd.
0.02
>-0.01
-20.00%
AU:IDT
IDT Australia Limited
0.04
-0.02
-26.67%
Epsilon Healthcare Limited Corporate Events
Epsilon Healthcare lifts quarterly receipts 34% as diversified platform gains scale
Oct 30, 2026
Epsilon Healthcare Limited reported strong growth for the quarter ended 30 September 2026, with customer receipts of $3.9 million, up 34 percent on the prior year’s corresponding quarter. The performance was driven by rising demand across it...
Epsilon Healthcare lifts revenue and builds integrated medicinal cannabis platform
Sep 27, 2026
Epsilon Healthcare reported a sharp turnaround in the first half of 2026, with revenue rising 123% to $7.59 million, positive EBITDA of $255,000, and net operating cash flow of $1.03 million, helped by stronger operating performance and lower one-...
Epsilon Healthcare Clarifies Managing Director Loan Was Unsecured
Sep 24, 2026
Epsilon Healthcare has clarified that a loan from its Managing Director, previously described as “secured” in several quarterly Appendix 4C cash flow reports, was in fact unsecured at all times. The company confirmed that no security i...
Epsilon Healthcare Director Boosts Equity Stake Through On-Market Share Purchase
Sep 17, 2026
Epsilon Healthcare Limited has disclosed a change in the shareholding of director Zoe Hutchings, in line with ASX listing rule requirements. The filing details her direct interests in fully paid ordinary shares and confirms that there were no chan...
Epsilon Healthcare Director Alan Beasley Boosts Shareholding via On-Market Purchases
Sep 10, 2026
Epsilon Healthcare Limited has disclosed a change in the holdings of director Alan Preston Beasley, who increased his direct stake in the company through on-market purchases. Over several transactions on 3, 4 and 10 September 2026, Beasley acquire...
Epsilon Healthcare Posts Record Quarter as Integrated Platform Scales
Jul 30, 2026
Epsilon Healthcare reported record customer receipts of $3.66 million for the June 2026 quarter, a 72% year‑on‑year increase and the highest quarterly figure in its history. Consolidated group revenue rose to $4.7 million for the quart...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.